Provectus Biopharmaceuticals, Inc. (PVCT)

USD 0.13

(-0.76%)

Market Cap (In USD)

54.63 Million

Revenue (In USD)

557.71 Thousand

Net Income (In USD)

-3.1 Million

Avg. Volume

276.39 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.045-0.225
PE
-
EPS
-
Beta Value
0.582
ISIN
US74373P1084
CUSIP
74373P108
CIK
315545
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Edward V. Pershing CPA
Employee Count
-
Website
https://www.provectusbio.com
Ipo Date
1997-01-15
Details
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver; uveal melanoma metastatic to the liver; and pediatric solid tumor cancers, such as neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. The company is also developing oral formulations of current good manufacturing practice rose bengal sodium (cGMP RBS) for the treatment of adult solid tumor cancers, such as head and neck, breast, testicular, and colorectal cancers; pediatric blood cancers, including leukemia; coronavirus, an acute respiratory syndrome; multi-drug resistant bacteria, such as gram-negative bacteria; and for eye diseases, including infectious keratitis. In addition, it develops PH-10, an investigational immuno-dermatology agent for the treatment of inflammatory dermatoses, such as psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennessee.